source
- CSL pays $355M upfront to co-develop Alentis’ phase-2 fibrosis drug lixudebartCSL of Australia has agreed to pay $355 million upfront for the rights to Alentis Therapeutics' anti-Claudin-1 drug lixudebart, a phase-2 fibrosis candidate. The agreement includes up to $1.2 bill…
- Genmab’s Rina-S ADC shows 9.5-month median PFS, touted as superior to AbbVie’s ElahereGenmab reported median progression‑free survival of 9.5 months for its FRα‑directed antibody‑drug conjugate Rina‑S in part C of the phase 1/2 Rainfol‑01 trial, which enrolled 109 patients with plat…